Login / Signup

Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.

Ida Kirstine Bull RasmussenEmilie H ZobelRasmus S RipaBernt J von ScholtenViktor Rotbain CurovicJacob K JensenAndreas KjaerTine Willum HansenPeter Rossing
Published in: Diabetes, obesity & metabolism (2021)
Treatment with liraglutide for 26 weeks was associated with a reduction in cardiac adipose tissue compared to placebo. The reduction was not independent of weight loss, suggesting that this is not a drug-specific effect.
Keyphrases